Perspective Therapeutics, Inc. (CATX) earnings
CATX earnings moved a median of -2.00% by the close. Quarterly and annual CATX reports and results, each read against the price at its own news timestamp. Back to the CATX overview →
20 measured CATX earnings events.
Where these CATX earnings landedvs 20 measured CATX earnings reactions
| Middle 50% of CATX earnings reactions | -4.53% to +2.72% |
|---|---|
| Median reaction (to close) | -2.00% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 CATX earnings events with a measured close landed between -4.53% and +2.72%; 35% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Perspective Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +4.49% | -8.09% | |
| Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results | Press release | -2.00% | -3.00% | |
| Form 10-Q Perspective Therapeutics For: Mar 31 | SEC filing · Form 10-Q | -3.82% | -7.14% | |
| Form 10-K Perspective Therapeutics For: Dec 31 | SEC filing · Form 10-K | -0.58% | -4.44% | |
| Form 10-Q Perspective Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +0.47% | +3.26% | |
| Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results | Press release | +0.51% | +1.70% | |
| Form 10-Q Perspective Therapeutics For: Jun 30 | SEC filing · Form 10-Q | -2.13% | -3.54% | |
| Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results | Press release | -0.25% | -1.51% | |
| Form 10-Q Perspective Therapeutics For: Mar 31 | SEC filing · Form 10-Q | +7.28% | -2.30% | |
| Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results | Press release | +0.54% | +4.87% | |
| Form 10-K/A Perspective Therapeutics For: Dec 31 | SEC filing · Form 10-K | -3.70% | -1.39% | |
| Form 10-K Perspective Therapeutics For: Dec 31 | SEC filing · Form 10-K | +2.23% | +2.68% | |
| Form 10-Q Perspective Therapeutics For: Sep 30 | SEC filing · Form 10-Q | -1.67% | -7.80% | |
| Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results | Press release | +2.81% | +3.60% | |
| Form 10-Q Perspective Therapeutics For: Jun 30 | SEC filing · Form 10-Q | +0.55% | +5.54% | |
| Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results | Press release | -0.08% | +2.84% | |
| Form 10-Q Perspective Therapeutics For: Mar 31 | SEC filing · Form 10-Q | -6.33% | -2.55% | |
| Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results | Press release | -0.83% | -13.26% | |
| Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results | Press release | +4.26% | -1.71% | |
| Form 10-K Perspective Therapeutics For: Dec 31 | SEC filing · Form 10-K | -1.20% | -4.80% |
Keep exploring
More CATX: analyst actions → · SEC filings → · CATX overview →